Biocept Inc (BIOC)

1.18
NASDAQ : Health Care
Prev Close 1.18
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.74 / 3.39
Avg Volume 504.10K
Exchange NASDAQ
Shares Outstanding 30.25M
Market Cap 36.30M
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Biocept Announces Private Placement Of $2.2 Million Of Common Stock With Ally Bridge LB Healthcare Master Fund

Biocept Announces Private Placement Of $2.2 Million Of Common Stock With Ally Bridge LB Healthcare Master Fund

Biocept and Ally Bridge to evaluate strategic opportunities in China for the Company's liquid biopsy platform

Biocept Executes Preferred Provider Agreement With Scripps Health Plan Expanding Patient Coverage For Its Liquid Biopsy Platform

Biocept Executes Preferred Provider Agreement With Scripps Health Plan Expanding Patient Coverage For Its Liquid Biopsy Platform

Prestigious Southern California health plan contracts with Biocept to make the Company's Target Selector™ tests available in-network for its patients with cancer

Biocept Expands Commercial Offering Of Clinically Actionable Biomarker Assays With Launch Of Liquid Biopsy Test For Progesterone Receptor Detection

Biocept Expands Commercial Offering Of Clinically Actionable Biomarker Assays With Launch Of Liquid Biopsy Test For Progesterone Receptor Detection

Biocept now offers 14 clinically actionable biomarker tests, including all validated biomarkers for breast cancer in NCCN Guidelines®

Biocept Awarded U.S. Patent With Broad Claims For Antibody Capture Of Targets Of Interest On Any Solid Surface Including CTCs And Other Materials Shed By Solid Tumors Into Blood

Company's intellectual property portfolio now features 20 issued patents protecting its proprietary liquid biopsy platform technology

Biocept's Target Selector Platform Featured In Three Clinical Abstracts At The 2017 American Society Of Clinical Oncology Annual Meeting Where Company Plans To Launch New Marketing Campaign

Abstracts feature clinical results demonstrating the high sensitivity of Biocept's Target Selector™ platform and the ability to identify mutations that may be missed by tissue biopsy

The Addario Lung Cancer Medical Institute And Biocept Announce Collaboration And Initiation Of Landmark ALCMI-009 Liquid Biopsy Clinical Trial In Lung Cancer

Large prospective multi-center clinical trial designed to evaluate the impact of cancer biomarker detection and serial monitoring using liquid biopsy to improve the outcomes of patients with lung cancer

Biocept Awarded Additional Patent In Japan Expanding Intellectual Property Estate To 19 Issued Patents Protecting Its Target Selector™ Liquid Biopsy Platform

New patent provides broad coverage for the use of antibodies to capture targets of interest, including circulating tumor cells (CTCs) and other materials shed by solid tumors into the blood stream

Biocept Announces Collaboration With The OHSU Knight Cancer Institute To Increase Clinical Adoption Of Liquid Biopsy Testing And To Co-Develop Additional Assay Platform Capabilities

NCI-designated cancer institute with leading molecular pathology lab obtains rights to utilize and commercially offer Biocept's Target Selector™ liquid biopsy services throughout the state of Oregon

Biocept Announces Revised Presentation Time At The 27th Annual Oppenheimer Healthcare Conference

Company presentation set for March 22 at 1:00 p.m. ET

Biocept And Catalyst Pharmaceuticals Collaborate To Provide Liquid Biopsy Testing For Small Cell Lung Cancer To Patients With Lambert Eaton Myasthenic Syndrome (LEMS)

Catalyst Pharmaceuticals to make Biocept's Target Selector™ test available to LEMS patients in Phase III Firdapse® trial to screen for cancer every six months for up to two years, at no cost to patients

These 5 Stocks Under $10 Could Explode Up Soon

These 5 Stocks Under $10 Could Explode Up Soon

Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.

Biocept's CEO Issues Letter To Stockholders

Highlights key accomplishments and outlines value drivers for 2017

Biocept Awarded Patent In Australia For The Use Of Antibodies In Microchannels To Capture Circulating Tumor Cells And Other Rare Cells

Biocept Awarded Patent In Australia For The Use Of Antibodies In Microchannels To Capture Circulating Tumor Cells And Other Rare Cells

Biocept further expands its global patent estate for capturing and detecting cells that are in very low abundance and that can provide important molecular information from biological fluids

Insider Trading Alert - BA, WLL And BIOC Traded By Insiders

Insider Trading Alert - BA, WLL And BIOC Traded By Insiders

Stocks with insider trader activity include BA, WLL and BIOC

8 Stocks Under $10 to Trade for Big Gains

8 Stocks Under $10 to Trade for Big Gains

These under-$10 stocks are making big moves higher. Here's how to trade them from here.

Biocept (BIOC) Stock Popping on Blue Cross Blue Shield Partnership

Biocept (BIOC) Stock Popping on Blue Cross Blue Shield Partnership

Biocept (BIOC) stock is surging in mid-morning trading on Tuesday after the company announced an agreement with Blue Cross Blue Shield of Illinois.

Rosetta Genomics And Biocept Advance Collaboration To Proof-of-Concept Studies Aimed At MicroRNA Profiling Of Circulating Tumor Cells To Enhance Lung Cancer Diagnosis

Rosetta Genomics And Biocept Advance Collaboration To Proof-of-Concept Studies Aimed At MicroRNA Profiling Of Circulating Tumor Cells To Enhance Lung Cancer Diagnosis

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, and Biocept, Inc.

Lung Cancer Study Demonstrates Extremely High Sensitivity Of Biocept's Blood-Based Liquid Biopsy Platform In Detecting EGFR Mutation In Plasma With 93% Concordance With Tissue Biopsy

Lung Cancer Study Demonstrates Extremely High Sensitivity Of Biocept's Blood-Based Liquid Biopsy Platform In Detecting EGFR Mutation In Plasma With 93% Concordance With Tissue Biopsy

Biocept, Inc. (NASDAQ: BIOC), a leading molecular diagnostics company commercializing and developing biomarkers used in liquid biopsies to improve the detection and treatment of cancer, today announced that findings...